2011 Annual Meeting | Is it MCI or Normal Aging?

Date Saturday 04/21/12

Time 02:00 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Victor W. Henderson, MD, FAAN

Topic(s)

Learning Objectives Participants should be familiar with current concepts of cognitive aging and MCI; neuropsychological, behavioral, and neuropathological features that help distinguish normal aging from MCI; and scientific evidence behind preventive strategies designed to maintain cognitive function during the aging process.

CME Available No CME available

Core Competencies Patient Care & Procedural Skills, Interpersonal and Communication Skills, Professionalism, Medical Knowledge, Systems-based Practice

Program Tracks Subspecialty in Focus

Recommended Audience Trainee, General Neurologist, Specialist Neurologist, Non-neurologist

Teaching Styles Didactic

Event Timeline
02:00 PM - 02:40 PM		Cognitive Aging and MCI: Current Concepts Victor W. Henderson, MD, FAAN
02:40 PM - 03:25 PM		Neuropsychological Features of Normal Aging and MCI David P. Salmon, PhD
03:25 PM - 04:10 PM		Neuropathological Correlates of Normal Aging and MCI Julie A. Schneider, MD, MS
04:10 PM - 04:25 PM		Break
04:25 PM - 05:10 PM		Preventive Strategies for Healthy Cognitive Aging Deborah E. Barnes, PhD, MPH
05:10 PM - 06:00 PM		Behavioral Features of Early MCI Michael D. Geschwind, MD, PhD, FAAN

Faculty Disclosures
Victor W. Henderson, MD, FAAN	Dr. Henderson has stock in Abbott, Amgen, Roche. The institution of Dr. Henderson has received research support from NIH. The institution of Dr. Henderson has received research support from Health IQ. Dr. Henderson has received personal compensation in the range of $500-$4,999 for serving as a External advisory committee member, Alzheimer's Disease Center with University of Kansas. Dr. Henderson has a non-compensated relationship as a adjunct (honorary) professor with Aarhus University that is relevant to AAN interests or activities.
Michael D. Geschwind, MD, PhD, FAAN	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
David P. Salmon, PhD	Dr. Salmon has nothing to disclose.
Deborah E. Barnes, PhD, MPH	The institution of Dr. Barnes has received research support from the National Institutes of Health, Department of Veterans Affairs, Department of Defense, Alzheimer's Association, and the California Department of Public Health.
Julie A. Schneider, MD, MS	Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for alnylam. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for apellis. Dr. Schneider has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for National Hockey League. The institution of Dr. Schneider has received research support from NIH. Dr. Schneider has received personal compensation in the range of $500-$4,999 for serving as a scientific advisor with Fondation Alzheimer, France.

��ɫ��

��ɫ��